These innovative agents represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://diegocdqf601011.look4blog.com/76918498/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide